Alchemia establishes level 1 ADR program
20 August, 2004 by Renate KrelleBrisbane biotech Alchemia (ASX: ACL) has taken the first step towards a NASDAQ listing, announcing it will be establishing a Level One American Depositary Receipt (ADR) program in coming months.
MCRI to build on CyGenics' stem cell scaffold
13 August, 2004 by Melissa TrudingerStem cell company CyGenics (ASX: CYN) will collaborate with the Murdoch Children's Research Institute to perform clinical trials demonstrating that stem cells expanded from umbilical cord blood using CyGenics subsidiary Cytomatrix's proprietary cell growth scaffold retain full functionality and effectiveness.
Vaxine wins Start grant and equity partner
12 August, 2004 by Graeme O'NeillThere’s a distinct, rosy glow on the commercial horizon for unlisted Canberra vaccine developer Vaxine, with the company winning a AUD$770,000 AusIndustry R&D Start grant to advance its new-generation hepatitis B vaccine, and bringing in an equity partner to boost its cash reserves.
Bioprospect and Bio-Gene team on eucalypt-derived flyspray
12 August, 2004 by Renate KrelleQueensland’s Bioprospect (ASX:BPO) has entered into a heads of agreement with Perth’s Bio-Gene Technology for the grow-out and distribution rights of Qcide, BioProspect’s eucalypt-derived natural insecticide.
Select develops test to detect Hepatitis A immunity
11 August, 2004 by Renate KrelleSelect Vaccines (ASX:SLT) announced today it has developed a rapid immunoglobulin G antibody assay to diagnose previous infection with the Hepatitis A virus (HAV).
National neurosciences facility launched
09 August, 2004 by Melissa TrudingerThe AUD$4.1 million Integrative Neuroscience Facility of the National Neuroscience Facility was opened today at the NNF headquarters in Melbourne.
Alchemia's synthetic heparin on track
05 August, 2004 by Melissa TrudingerAlchemia (ASX: ACL) has completed the scale-up of its manufacturing process for synthetic heparin on schedule.
NSCC and Nephrogenix to explore origins of kidney, bone
03 August, 2004 by Melissa TrudingerThe National Stem Cell Centre (NSCC) has signed a research collaboration agreement with Nephrogenix, the company responsible for commercialising outcomes from the Renal Regeneration Consortium (RRC), which is investigating kidney development and regeneration.
NSCC and ESI strike stem cell accord
20 July, 2004 by Melissa TrudingerThe National Stem Cell Centre has signed a collaboration agreement with Singapore-based ES Cell International (ESI) to develop new human embryonic stem cell-based treatments for diabetes and other diseases.
Bioprospect isolates termite-repellent
19 July, 2004 by Graeme O'NeillEvolutionary biologists talk about a perpetual arms race between predators and prey -- an unwinnable war in which one combatant achieves a transient advantage before the other develops a counter-measure. But it seems that at least one native hardwood of Australia's tropical north found a game-ending defence against termites that keeps its wood nice long after it expires.
Synchrotron pulls in $5m from ANSTO
01 July, 2004 by Melissa TrudingerThe Australian Synchrotron project has scored another AUD$5 million funding for the initial suite of beamlines from the Australian Nuclear Science and Technology Organisation (ANSTO), which joins the University of Melbourne, Monash University, CSIRO and MiniFAB as a foundation partner.
Sydney IVF produces stem cells
24 June, 2004 by Susan WilliamsonFertility clinic Sydney IVF has obtained stem cells from an Australian embryo, which it will make available to stem cell researchers.
Norwood Immunology aims to beat European IPO blues
24 June, 2004 by Renate KrelleNorwood Abbey Ltd [ASX:NAL NASDAQ:NABYF] is close to snatching victory from the jaws of a hostile London investment market, announcing today that its subsidiary Norwood Immunology will list next Wednesday on London’s Alternative Investment Market (AIM), selling 15 million shares and raising AUD$15 million.
News: 300km/h on the wind superhighway
21 June, 2004 by Graeme O'NeillHow do plant pathogens proliferate? Graeme O'Neill finds that new research suggests the answer is blowin' in the wind.
NSCC, Stem Cell Sciences to team up on ES cell lines
07 June, 2004 by Melissa TrudingerStem Cell Sciences (SCS), the former Melbourne company now based in the UK, is to collaborate with Australia's National Stem Cell Centre on new human embryonic stem cell lines to be derived by SCS and Melbourne IVF.
